Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previous two years. The medication will be sold under the brand name Cenrifki. The decision, which is in line with a…
tolebrutinib
Recommended Posts
- Early treatment may ease long-term disability in progressive MS
- Experimental therapy may curb chronic brain inflammation in MS
- Small Thai study finds high malnutrition risk rate in MS patients
- Christina Applegate’s MS misdiagnosis sparks discussion
- Pain linked to perceived cognitive difficulties in MS study